Figure 4.
Cumulative percent change in BMD from baseline, denosumab vs. placebo in men with prostate cancer receiving ADT.126
Notes: Results are presented as least-squares means.
Abbreviation: BMD, bone mineral density.
Cumulative percent change in BMD from baseline, denosumab vs. placebo in men with prostate cancer receiving ADT.126
Notes: Results are presented as least-squares means.
Abbreviation: BMD, bone mineral density.